company background image
PAA

PharmAust ASX:PAA Stock Report

Last Price

AU$0.076

Market Cap

AU$24.1m

7D

-5.0%

1Y

-9.5%

Updated

28 Sep, 2022

Data

Company Financials
PAA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

PAA Stock Overview

PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally.

PharmAust Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for PharmAust
Historical stock prices
Current Share PriceAU$0.076
52 Week HighAU$0.12
52 Week LowAU$0.065
Beta0.75
1 Month Change-9.52%
3 Month Change8.57%
1 Year Change-9.52%
3 Year Change-49.33%
5 Year Change52.00%
Change since IPO-99.16%

Recent News & Updates

May 30
Is PharmAust (ASX:PAA) In A Good Position To Deliver On Growth Plans?

Is PharmAust (ASX:PAA) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Shareholder Returns

PAAAU PharmaceuticalsAU Market
7D-5.0%-4.6%-3.3%
1Y-9.5%-25.2%-10.6%

Return vs Industry: PAA exceeded the Australian Pharmaceuticals industry which returned -25.2% over the past year.

Return vs Market: PAA exceeded the Australian Market which returned -10.6% over the past year.

Price Volatility

Is PAA's price volatile compared to industry and market?
PAA volatility
PAA Average Weekly Movement9.2%
Pharmaceuticals Industry Average Movement10.9%
Market Average Movement9.6%
10% most volatile stocks in AU Market16.7%
10% least volatile stocks in AU Market4.3%

Stable Share Price: PAA is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: PAA's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2000n/aRoger Astonhttps://www.pharmaust.com

PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers, and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of cancer.

PharmAust Limited Fundamentals Summary

How do PharmAust's earnings and revenue compare to its market cap?
PAA fundamental statistics
Market CapAU$24.09m
Earnings (TTM)-AU$1.71m
Revenue (TTM)AU$4.51m

5.3x

P/S Ratio

-14.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PAA income statement (TTM)
RevenueAU$4.51m
Cost of RevenueAU$314.34k
Gross ProfitAU$4.20m
Other ExpensesAU$5.90m
Earnings-AU$1.71m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.0054
Gross Margin93.03%
Net Profit Margin-37.87%
Debt/Equity Ratio2.7%

How did PAA perform over the long term?

See historical performance and comparison